FAQs

Answering Your Frequently Asked Questions

Prepare for the 7th TCR-Based Therapies Summit with this comprehensive FAQ guide covering information on registration, agenda themes, scientific sessions, partnership opportunities and more. This resource is designed to help you navigate the most targeted TCR Conference in the field.

Can't find what you're looking for? Get in touch at [email protected] for more information.

General

General

Is the 7th TCR-Based Therapies Summit a dedicated meeting focused exclusively on TCR-based therapies?

Where is the summit taking place?

Who can I expect to meet?

At the 7th TCR-Based Therapies Summit, you can expect to meet 70+ TCR experts from across biotech, pharma, and academia, providing an intimate and highly focused networking environment.

Confirmed organizations include leading TCR innovators such as Immunocore, Immatics, Zelluna Immunotherapy, Enara Bio, Eureka Therapeutics, Regeneron, BioNTech, Anocca, Marengo Therapeutics, T‑knife Therapeutics, 3T Biosciences, Crossbow Therapeutics, MD Anderson Cancer Center and more.

With over 55% of expert speakers at Chief/VP level, this is a close‑knit TCR‑focused meeting is designed to enable meaningful peer‑to‑peer discussion and partnership building.

Event Content

Is this event different from broader meetings, including general CAR‑T and T‑Cell Engager conferences?

Does the 7th TCR-Based Therapies Summit offer a more intimate and targeted environment compared with multi-track cell and gene therapy or protein engineering conferences?

Will the 2026 summit include brand‑new or unpublished data presentations?

Is this just an oncology-targeting cell therapy meeting?

Will AI, machine learning, and advanced computational tools be discussed in the context of TCR engineering?

Will there be pre‑conference workshops exploring next‑generation engineering and target discovery?

Attendance

Is the 7th TCR-Based Summit designed for senior-level scientific and clinical leaders?

Is the summit suitable for teams working on early discovery through clinical development?

Can attendees expect opportunities to build partnerships that directly impact their TCR pipeline?

Does the meeting include structured networking opportunities with the TCR community?

Partnership

Why should I partner?

Partnering with the 7th TCR-Based Therapies Summit positions your company at the center of the global TCR community at a defining moment for the field. Partnership offers direct access to a highly targeted audience of senior TCR developers actively evaluating solutions across discovery, sequencing, HLA typing, immune profiling, companion diagnostics, preclinical models, and manufacturing optimization. Unlike large, multi‑track CAR‑T and T‑Cell Engager conferences, this meeting enables deeper engagement, stronger brand alignment, and meaningful relationship building within an intimate, high‑intent environment to maximize impact and return on investment.

Are there any partnership slots still available?

Yes. A limited number of bespoke partnership opportunities are still available, designed for companies supporting critical needs across TCR discovery and sequencing, HLA typing, immune profiling, companion diagnostics, preclinical models, and manufacturing optimization.

If your solutions align with this, get in touch here to discuss how our tailored partnership packages can support your specific strategic and commercial goals.

Does partnering allow companies to engage with a highly curated, decision‑making TCR audience?

Who should I contact to explore partnership opportunities?